These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22436083)

  • 1. A pilot open label prospective study of memantine monotherapy in adults with ADHD.
    Surman CB; Hammerness PG; Petty C; Spencer T; Doyle R; Napolean S; Chu N; Yorks D; Biederman J
    World J Biol Psychiatry; 2013 May; 14(4):291-8. PubMed ID: 22436083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type.
    Findling RL; McNamara NK; Stansbrey RJ; Maxhimer R; Periclou A; Mann A; Graham SM
    J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):19-33. PubMed ID: 17343551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine reduces stealing behavior and impulsivity in kleptomania: a pilot study.
    Grant JE; Odlaug BL; Schreiber LR; Chamberlain SR; Won Kim S
    Int Clin Psychopharmacol; 2013 Mar; 28(2):106-11. PubMed ID: 23299454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot double-blind treatment trial of memantine for alcohol dependence.
    Evans SM; Levin FR; Brooks DJ; Garawi F
    Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
    Ferris S; Schneider L; Farmer M; Kay G; Crook T
    Int J Geriatr Psychiatry; 2007 May; 22(5):448-55. PubMed ID: 17117395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation.
    Keck PE; Hsu HA; Papadakis K; Russo J
    Clin Neuropharmacol; 2009; 32(4):199-204. PubMed ID: 19620854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
    Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
    AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does memantine improve memory in subjects with focal-onset epilepsy and memory dysfunction? A randomized, double-blind, placebo-controlled trial.
    Leeman-Markowski BA; Meador KJ; Moo LR; Cole AJ; Hoch DB; Garcia E; Schachter SC
    Epilepsy Behav; 2018 Nov; 88():315-324. PubMed ID: 30449328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.
    Herring WJ; Wilens TE; Adler LA; Baranak C; Liu K; Snavely DB; Lines CR; Michelson D
    J Clin Psychiatry; 2012 Jul; 73(7):e891-8. PubMed ID: 22901359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
    Brown TE; Brams M; Gao J; Gasior M; Childress A
    Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
    Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
    J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.